Broad spectrum antibody-mediated neutralization

Broad spectrum antibody-mediated neutralization" refers to the process whereby certain antibodies, often termed 'broadly neutralizing antibodies' (bnAbs), neutralize a range of viral strains or species by binding to conserved structural regions (epitopes) on the pathogen surface. These antibodies can prevent viral entry into host cells by blocking receptor binding, inhibiting fusion processes, or inducing conformational changes in viral proteins that render them non-infectious. This broad activity is of particular importance for therapies and vaccines targeting variable viruses such as HIV-1, Influenza, and SARS-CoV-2, where eliciting or administering bnAbs can provide protection against multiple viral variants. This term does not refer to a specific molecule or canonical drug target, but rather to an immunological mechanism and strategy[9][2][7][4][5]. Essential clarification: "Broad spectrum antibody-mediated neutralization" is **not** the name of a distinct molecular target (e.g., a receptor or protein), but rather describes a **mechanism of immune defense** typically harnessed in immunotherapy or vaccination contexts. Drug development in this area focuses on the antibodies themselves (e.g., VRC01, nirsevimab, iMab/D5_AR)[5][4][7], not on a single target molecule bearing this name.

Other names

broadly neutralizing antibody responsebroad-spectrum antibody neutralizationantibody-mediated broad neutralization

Binding to conserved viral epitopes to prevent infection; Inhibiting virus-cell fusion; Blocking viral entry into host cells; Triggering irreversible changes in viral particles